Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer

Leire Arrizabalaga; Esmeralda García-Torralba; Lorenzo Galluzzi; Aitziber Buqué

doi:10.1016/j.molmed.2024.12.009

Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer

Leire Arrizabalaga, Esmeralda García-Torralba, Lorenzo Galluzzi, Aitziber Buqué

Fox Chase Cancer Center

Research output: Contribution to journal › Article › peer-review

Abstract

Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR+ breast cancer. Recent data from Kudo et al. demonstrate that CDK2-targeting agents may offer an effective strategy to circumvent such resistance by enforcing cellular senescence downstream of RBL2 dephosphorylation.

Original language	English
Journal	Trends in Molecular Medicine
DOIs	https://doi.org/10.1016/j.molmed.2024.12.009
State	E-pub ahead of print - Nov 27 2024

Keywords

RB1
type I interferon
DREAM complex
MDM2
immune checkpoint inhibitors
non-oncogene addiction

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.molmed.2024.12.009

Cite this

@article{73f36cf6bd554c18b983987d54eab42c,

title = "Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer",

abstract = "Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR+ breast cancer. Recent data from Kudo et al. demonstrate that CDK2-targeting agents may offer an effective strategy to circumvent such resistance by enforcing cellular senescence downstream of RBL2 dephosphorylation.",

keywords = "RB1, type I interferon, DREAM complex, MDM2, immune checkpoint inhibitors, non-oncogene addiction",

author = "Leire Arrizabalaga and Esmeralda Garc{\'i}a-Torralba and Lorenzo Galluzzi and Aitziber Buqu{\'e}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = nov,

day = "27",

doi = "10.1016/j.molmed.2024.12.009",

language = "English",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer

AU - Arrizabalaga, Leire

AU - García-Torralba, Esmeralda

AU - Galluzzi, Lorenzo

AU - Buqué, Aitziber

PY - 2024/11/27

Y1 - 2024/11/27

N2 - Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR+ breast cancer. Recent data from Kudo et al. demonstrate that CDK2-targeting agents may offer an effective strategy to circumvent such resistance by enforcing cellular senescence downstream of RBL2 dephosphorylation.

AB - Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR+ breast cancer. Recent data from Kudo et al. demonstrate that CDK2-targeting agents may offer an effective strategy to circumvent such resistance by enforcing cellular senescence downstream of RBL2 dephosphorylation.

KW - RB1

KW - type I interferon

KW - DREAM complex

KW - MDM2

KW - immune checkpoint inhibitors

KW - non-oncogene addiction

UR - http://www.scopus.com/inward/record.url?scp=85213571614&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2024.12.009

DO - 10.1016/j.molmed.2024.12.009

M3 - Article

C2 - 39732571

SN - 1471-4914

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

ER -

Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this